Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Go back to Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy| Soligenix, Inc. (NASDAQ: SNGX) | Delayed: 0.38 -0.01 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.39 | 52 Week High | $4.35 | |||
| Open | $0.39 | 52 Week Low | $0.44 | |||
| Day High | $0.41 | P/E | N/A | |||
| Day Low | $0.38 | EPS | $-0.81 | |||
| Volume | 743,461 | |||||
